Mirapexin prolonged release formulation launched

A once daily formulation of pramipexole (Mirapexin Prolonged Release) has been launched for the treatment of idiopathic Parkinson's disease.

The new preparation is available in five strengths: 0.26mg, 0.52mg, 1.05mg, 2.1mg and 3.15mg.
Treatment with Mirapexin Prolonged Release should be initiated at 0.26mg daily, increasing to a maximum of 3.15mg per day as necessary.

View Mirapexin drug record

Further information: Boehringer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

First COVID-19 vaccine approved for use in the UK from next week

First COVID-19 vaccine approved for use in the UK from next week

The MHRA has approved the COVID-19 vaccine developed...

SGLT2 inhibitors summarised in new MIMS table

SGLT2 inhibitors summarised in new MIMS table

Prescribers can quickly compare key features and benefits...